Elixir Medical Corporation - Product Pipeline Analysis, 2014 Update

Date: August 6, 2014
Pages: 35
Price:
US$ 750.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CC340D7E626EN
Leaflet:

Download PDF Leaflet

Elixir Medical Corporation - Product Pipeline Analysis, 2014 Update
Summary

Elixir Medical Corporation (Elixir Medical) is a medical device manufacturer. The company manufactures and distributes drug eluting stent systems for localized drug delivery used in the treatment of cardiovascular diseases. It provides drug-device treatment solutions to patients worldwide. Elixir Medical’s product includes innovating vascular restoration product. The company has a presence in Ireland and the US. Elixir Medical is headquartered in Sunnyvale, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Elixir Medical Corporation
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Elixir Medical Corporation Company Snapshot
Elixir Medical Corporation Company Overview
Key Information
Elixir Medical Corporation Pipeline Products and Clinical Trials Overview
Elixir Medical Corporation – Pipeline Analysis Overview
Key Facts
Elixir Medical Corporation - Major Products and Services
Elixir Medical Corporation Pipeline Products by Development Stage
Elixir Medical Corporation Clinical Trials by Trial Status
Elixir Medical Corporation Pipeline Products Overview
DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System
DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System Product Overview
DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System
DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System Product Overview
DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System Clinical Trial
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System Product Overview
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System Clinical Trial
DESyne BD Novolimus Eluting Coronary Stent System
DESyne BD Novolimus Eluting Coronary Stent System Product Overview
DESyne BD Novolimus Eluting Coronary Stent System Clinical Trial
DESyne Nx Novolimus Eluting Coronary Stent System
DESyne Nx Novolimus Eluting Coronary Stent System Product Overview
DESyne Nx Novolimus Eluting Coronary Stent System Clinical Trial
Myolimus Eluting Coronary Stent - Durable Polymer
Myolimus Eluting Coronary Stent - Durable Polymer Product Overview
Elixir Medical Corporation - Key Competitors
Elixir Medical Corporation - Key Employees
Elixir Medical Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Elixir Medical Corporation, Recent Developments
May 21, 2014: Successful Live Case Demonstration of Elixir Medical’s CE Mark-Approved Fully Bioresorbable DESolve 100 Novolimus Eluting Coronary Scaffold System at EuroPCR
May 14, 2014: Elixir Medical to Showcase a Live Case Demonstration of the Breakthrough Fully Bioresorbable DESolve 100 Novolimus Eluting Coronary Scaffold System at EuroPCR
May 13, 2014: Elixir Medical's DESolve 100 Novolimus Eluting Coronary Scaffold System Gets CE Mark
Jan 15, 2014: Elixir Medical Reports First Commercial Implant Of DESolve Scaffold System In Europe
Jan 06, 2014: Elixir Medical to Present at J.P. Morgan Healthcare Conference
Oct 31, 2013: Elixir Medical Announces Excellent 1-year Safety and Efficacy Results for the CE-Marked Fully Bioresorbable DESolve Novolimus Eluting Coronary Scaffold System
May 24, 2013: Elixir Medical Announces Positive Two-Year Results From EXCELLA BD Randomized Clinical Trial For DESyne BD System With Biodegradable Polymer Coating
May 21, 2013: Elixir Medical Reports Positive Six-Month Results For DESolve Novolimus Eluting Coronary Scaffold System At EuroPCR 2013
May 15, 2013: Elixir Medical Gets CE Mark For DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System
May 08, 2013: Elixir Medical Gets FDA Approval To Commence EXCELLA III Clinical Trial With DESyne Nx Novolimus Eluting Coronary Stent System In US
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Elixir Medical Corporation, Key Facts
Elixir Medical Corporation Pipeline Products and Clinical Trials Overview
Elixir Medical Corporation Pipeline Products by Equipment Type
Elixir Medical Corporation Pipeline Products by Indication
Elixir Medical Corporation Clinical Trials by Trial Status
Elixir Medical Corporation, Key Facts
Elixir Medical Corporation, Major Products and Services
Elixir Medical Corporation Number of Pipeline Products by Development Stage
Elixir Medical Corporation Pipeline Products Summary by Development Stage
Elixir Medical Corporation Clinical Trials by Trial Status
Elixir Medical Corporation Clinical Trials Summary
DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Status
DESolve 100 Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Description
DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System - Product Status
DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System - Product Description
DESolve Myolimus Eluting Bioresorbable Coronary Scaffold System - First-In-Man Study Of The Myolimus Eluting Coronary Stent System
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Status
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - Product Description
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - A Non-Randomized Trial To Study The Safety And Performance Of The Desolve Bioresorbable Coronary System In Patients With Single, De Novo Coronary Artery Blockages
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - A Non-randomized, Consecutive Enrollment Evaluation of the Desolve Myolimus Eluting Bioresorbable Coronary Stent System in the Treatment of Patients with De Novo Native Coronary Artery Lesions
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - A Non-randomized, Consecutive Enrollment Evaluation of the Desolve Novolimus Eluting Bioresorbable Coronary Scaffold System in the Treatment of Patients with De Novo Native Coronary Artery Lesions
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - DESolve Novolimus Eluting Coronary Scaffold System Using Multi Slice Coherence Tomography(MSCT), A Noninvasive Imaging Modality To visualize Coronary Arteries
DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System - Post-market Evaluation of Desolve Novolimus Eluting Bioresorbable Coronary Scaffold System in the Treatment of Patients with De Novo Native Coronary Artery Lesions
DESyne BD Novolimus Eluting Coronary Stent System - Product Status
DESyne BD Novolimus Eluting Coronary Stent System - Product Description
DESyne BD Novolimus Eluting Coronary Stent System - Post Marketing Study of the Elixir Desyne Novolimus Eluting Coronary Stent System and the Desyne BD Novolimus Eluting Coronary Stent System in the Treatment of Patients with De Novo Native Coronary Artery Lesions
DESyne Nx Novolimus Eluting Coronary Stent System - Product Status
DESyne Nx Novolimus Eluting Coronary Stent System - Product Description
DESyne Nx Novolimus Eluting Coronary Stent System - A Randomized, Single Blind, Consecutive Enrollment Evaluation of The Elixir Novolimus-Eluting Coronary Stent System With Durable Polymer Compared to the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions and a Non-Randomized, Consecutive Enrollment Evaluation of the Elixir Novolimus-Eluting Coronary Stent System With Bioabsorbable Polymer Compared to Contemporary Controls in the Treatment of Patients With De Novo Native Coronary Artery Lesions
DESyne Nx Novolimus Eluting Coronary Stent System - Evaluation of the Novolimus-Eluting Coronary Stent System: A Randomized Study
Myolimus Eluting Coronary Stent - Durable Polymer - Product Status
Myolimus Eluting Coronary Stent - Durable Polymer - Product Description
Elixir Medical Corporation, Key Employees
Elixir Medical Corporation, Other Locations

LIST OF FIGURES

Elixir Medical Corporation Pipeline Products by Equipment Type
Elixir Medical Corporation Pipeline Products by Development Stage
Elixir Medical Corporation Clinical Trials by Trial Status
Skip to top


Ask Your Question

Elixir Medical Corporation - Product Pipeline Analysis, 2014 Update
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: